PE20080428A1 - Vacunas para la malaria - Google Patents

Vacunas para la malaria

Info

Publication number
PE20080428A1
PE20080428A1 PE2007000913A PE2007000913A PE20080428A1 PE 20080428 A1 PE20080428 A1 PE 20080428A1 PE 2007000913 A PE2007000913 A PE 2007000913A PE 2007000913 A PE2007000913 A PE 2007000913A PE 20080428 A1 PE20080428 A1 PE 20080428A1
Authority
PE
Peru
Prior art keywords
protein
vivax
repetition
region
seq
Prior art date
Application number
PE2007000913A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Christian F Ockenhouse
Anjali Yadava
Original Assignee
Glaxosmithkline Biolog Sa
Us Secretary Of The Army F T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Secretary Of The Army F T filed Critical Glaxosmithkline Biolog Sa
Publication of PE20080428A1 publication Critical patent/PE20080428A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION HIBRIDA INMUNOGENICA QUE COMPRENDE: A) AL MENOS UNA UNIDAD DE REPETICION DERIVADA DE LA REGION DE REPETICION DE UNA PROTEINA DE CIRCUMSPOROZOITO DE TIPO I DE P. VIVAX SELECCIONADA ENTRE UNO O MAS MONOMEROS DE LA SEQ ID Nº 3 A 9; B) AL MENOS UNA UNIDAD DE REPETICION DERIVADA DE LA REGION DE REPETICION DE UNA PROTEINA DE CIRCUMSPOROZOITO DE TIPO II DE P. VIVAX SELECCIONADO ENTRE 1 0 MAS MONOMEROS DE SEQ ID Nº10 o 14; C) ANTIGENO S DE SUPERFICIE DERIVADO DEL VIRUS DE HEPATITIS B, O UN FRAGMENTO DEL MISMO SELECCIONADO DE DBP, PvTRAP, PvMSP2, PvMSP4, ENTRE OTROS; D) UN ADYUVANTE SELECCIONADO DE SAPONINA, 3D-MPL, LIPOSOMA, ISCOM; TENSIOACTIVO SELECCIONADO ENTRE TWEEN 20, BRIJI, POLIETILENGLICOL,. DICHA PROTEINA COMPRENDE ADEMAS UN FRAGMENTO N TERMINAL DE LA PROTEINA CS DE P. VIVAX CONOCIDO COMO LA REGION (I) TAL COMO SE MUESTRA EN LA SEQ ID Nº 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE MALARIA PROVOCADA POR PLASMODIUM VIVAX
PE2007000913A 2006-07-18 2007-07-16 Vacunas para la malaria PE20080428A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
PE20080428A1 true PE20080428A1 (es) 2008-05-15

Family

ID=38957130

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000913A PE20080428A1 (es) 2006-07-18 2007-07-16 Vacunas para la malaria

Country Status (22)

Country Link
US (2) US9364525B2 (es)
EP (2) EP2040743B1 (es)
JP (2) JP5592110B2 (es)
KR (2) KR20090092752A (es)
AR (1) AR061894A1 (es)
AU (2) AU2007276219B2 (es)
BR (2) BRPI0715581A2 (es)
CA (2) CA2657279A1 (es)
CO (2) CO6150187A2 (es)
CR (2) CR10555A (es)
EA (2) EA200900033A1 (es)
ES (2) ES2437082T3 (es)
IL (2) IL196410A0 (es)
MA (2) MA30671B1 (es)
MX (2) MX2009000650A (es)
NO (2) NO20090178L (es)
NZ (2) NZ574239A (es)
PE (1) PE20080428A1 (es)
SG (2) SG173377A1 (es)
TW (1) TW200819462A (es)
WO (2) WO2008009650A2 (es)
ZA (1) ZA200900386B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
EP3108899A1 (en) 2001-11-21 2016-12-28 The Trustees of the University of Pennsylvania Simian adenovirus adsv1 nucleic acid and amino acid sequences, vectors containing same, and methods of use
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
JP2011505796A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US8999347B2 (en) * 2007-12-24 2015-04-07 Glaxosmithkline Biologicals, Sa Vaccines for malaria
AU2009297127A1 (en) * 2008-09-24 2010-04-01 The Government Of The United States, As Represented By The Secretary Of The Army Malaria vaccine
CA2742474C (en) * 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
EP2945649B1 (en) * 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition and uses thereof
EP3213638A1 (en) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Vegan cheese analogue
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
AU2017393085B2 (en) * 2016-12-23 2024-02-29 The Walter And Eliza Hall Institute Of Medical Research System, method, apparatus and diagnostic test for Plasmodium vivax
WO2022059089A1 (ja) 2020-09-16 2022-03-24 三菱電機株式会社 前照灯装置

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
EP0229829B1 (en) * 1985-07-12 1995-02-22 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DE69228698T2 (de) * 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
WO1995007353A2 (en) 1993-09-10 1995-03-16 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20030133944A1 (en) * 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ATE355266T1 (de) 1998-06-30 2006-03-15 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
WO2001034188A1 (en) 1999-11-12 2001-05-17 University Of Hawaii Malaria vaccine
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
KR20040043129A (ko) 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
ES2385481T3 (es) 2003-06-20 2012-07-25 Siemens Healthcare Diagnostics Products Gmbh Nueva variante de proteína de superficie (HbsAg) del virus de hepatitis B
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US20050233435A1 (en) 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
CA2593643C (en) * 2005-01-18 2016-03-22 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
US8999347B2 (en) * 2007-12-24 2015-04-07 Glaxosmithkline Biologicals, Sa Vaccines for malaria

Also Published As

Publication number Publication date
EA200900033A1 (ru) 2009-12-30
JP2009543846A (ja) 2009-12-10
MA30671B1 (fr) 2009-08-03
SG173363A1 (en) 2011-08-29
CR10555A (es) 2009-04-29
MX2009000655A (es) 2009-07-02
EP2040742B1 (en) 2014-10-29
TW200819462A (en) 2008-05-01
US9364525B2 (en) 2016-06-14
KR20090094213A (ko) 2009-09-04
ES2437082T3 (es) 2014-01-08
ES2525732T3 (es) 2014-12-29
SG173377A1 (en) 2011-08-29
KR20090092752A (ko) 2009-09-01
JP2009543569A (ja) 2009-12-10
ZA200900386B (en) 2014-03-26
AU2007276219A1 (en) 2008-01-24
EA200900032A1 (ru) 2011-02-28
NO20090177L (no) 2009-02-16
WO2008009652A3 (en) 2008-05-08
NO20090178L (no) 2009-02-09
JP5222289B2 (ja) 2013-06-26
WO2008009652A2 (en) 2008-01-24
CO6150189A2 (es) 2010-04-20
MA30670B1 (fr) 2009-08-03
US20100150998A1 (en) 2010-06-17
MX2009000650A (es) 2009-07-02
US20100062028A1 (en) 2010-03-11
AR061894A1 (es) 2008-10-01
BRPI0715581A2 (pt) 2013-04-24
WO2008009650A2 (en) 2008-01-24
JP5592110B2 (ja) 2014-09-17
IL196410A0 (en) 2011-08-01
EP2040743A2 (en) 2009-04-01
CO6150187A2 (es) 2010-04-20
EP2040742A2 (en) 2009-04-01
EP2040743B1 (en) 2013-10-02
CA2657353A1 (en) 2008-01-24
AU2007276217A8 (en) 2009-02-26
AU2007276217B2 (en) 2013-08-29
NZ574238A (en) 2012-02-24
IL196471A0 (en) 2011-08-01
NZ574239A (en) 2011-12-22
BRPI0714326A2 (pt) 2013-05-07
CA2657279A1 (en) 2008-01-24
CR10561A (es) 2009-04-29
AU2007276217A1 (en) 2008-01-24
US9592282B2 (en) 2017-03-14
WO2008009650A3 (en) 2008-04-10
AU2007276219B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
PE20080428A1 (es) Vacunas para la malaria
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
NO20072470L (no) Malariaigangsetter/forsterkervaksine
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20140844A1 (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
WO2007011904A3 (en) Recombinant flu vaccines
SI1951296T2 (sl) Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
PE20100658A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL
TR201901649T4 (tr) Nematodların ve toprak kaynaklı hastalıkların kontrolüne yönelik bileşimler ve yöntemler.
AR065523A1 (es) Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones
WO2009022236A3 (en) Immunogen platform
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
EA200701911A1 (ru) Химерные рекомбинантные антигены toxoplasma gondii
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
WO2009130588A3 (en) Codon-optimzed hepatitis b virus core antigen (hbcag)
UA108081C2 (uk) Модифікація рекомбінантного аденовірусу імуногенними епітопами білка circumsporozoite плазмодія
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
BRPI0613362A8 (pt) polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
AR095482A1 (es) Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso
PE20081687A1 (es) Proteina de fusion
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed